Higher expression level of tyrosine kinase‑like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis

Chen,Liang; Zhao,Lianmei; Ding,Mingjian; Yang,Meng; Yang,Wenhua; Cui,Guozhong; Shan,Baoen

doi:10.3892/ol.2017.6989

Higher expression level of tyrosine kinase‑like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis

Authors:
- Liang Chen
- Lianmei Zhao
- Mingjian Ding
- Meng Yang
- Wenhua Yang
- Guozhong Cui
- Baoen Shan
View Affiliations

Affiliations: Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Oncology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China
Published online on: September 18, 2017 https://doi.org/10.3892/ol.2017.6989
Pages: 5966-5972
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tyrosine kinase‑like orphan receptor 2 (ROR2) has a wnt‑mediated, pro‑tumorigenic role in certain types of cancer. The present study was designed to assess the protein expression level of ROR2 and its putative ligand Wnt member 5a (Wnt5a), as well as the association with clinicopathological features in papillary thyroid carcinoma (PTC). A total of 58 patients were recruited, resulting in 58 human PTC tissue samples and their paired adjacent noncancerous tissue samples being obtained. The protein expression levels of ROR2 and Wnt5a were evaluated by immunohistochemistry and western blotting, and messenger RNA expression levels were determined by reverse transcription‑quantitative polymerase chain reaction. ROR2 and Wnt5a protein and mRNA expression were significantly overexpressed in PTC tissues (P<0.05). The present study also revealed that ROR2 and Wnt5a were significantly associated with tumor stage and lymph node metastasis (P<0.05). There was a positive association between ROR2 and Wnt5a expression levels (r=0.857; P=0.007). In conclusion, ROR2 and Wnt5a may act as tumor suppressor genes in the development of PTC; overexpression of ROR2 and Wnt5a in PTC may be important for tumorigenesis and tumor development.

View Figures

View References

1	Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
2	La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer mortality and incidence: A global overview. Int J Cancer. 136:2187–2195. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zimmermann MB and Galetti V: Iodine intake as a risk factor for thyroid cancer: A comprehensive review of animal and human studies. Thyroid Res. 8:82015. View Article : Google Scholar : PubMed/NCBI
4	Jeon MJ, Kim WG, Choi YM, Kwon H, Lee YM, Sung TY, Yoon JH, Chung KW, Hong SJ, Kim TY, et al: Features predictive of distant metastasis in papillary thyroid microcarcinoma. Thyroid. 26:161–168. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lara E, Calvanese V, Huidobro C, Fernández AF, Moncada-Pazos A, Obaya AJ, Aguilera O, González-Sancho JM, Sánchez L, Astudillo A, et al: Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer. 9:1702010. View Article : Google Scholar : PubMed/NCBI
6	Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, et al: Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. PLoS One. 9:e1161012014. View Article : Google Scholar : PubMed/NCBI
7	International Agency for Research on Cancer: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA, Lloyd VR, Heitz PU and Eng C: IARC Press; Lyon, France: 8. 3rd. pp. 3202004
8	Sastre-Perona A and Santisteban P: Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne). 3:312012.PubMed/NCBI
9	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
10	Lim H, Devesa SS, Sosa JA, Check D and Kitahara CM: Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
11	La Greca A, Xu B, Ghossein R, Tuttle RM and Sabra MM: Patients with multifocal macroscopic papillary thyroid carcinoma have a low risk of recurrence at early follow-up after total thyroidectomy and radioactive iodine treatment. Eur Thyroid J. 6:31–39. 2017. View Article : Google Scholar : PubMed/NCBI
12	Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, et al: Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987–2012. J Clin Endocrinol Metab. 100:3270–3279. 2015. View Article : Google Scholar : PubMed/NCBI
13	Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J and Riggins GJ: Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res. 12:3311–3318. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF and Shi Y: Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 24:1256–1266. 2014. View Article : Google Scholar : PubMed/NCBI
15	Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, et al: Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion. Oncotarget. 6:40310–40326. 2015. View Article : Google Scholar : PubMed/NCBI
16	Kim YH, Choi YW, Han JH, Lee J, Soh EY, Park SH, Kim JH and Park TJ: TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6. Neoplasia. 16:1107–1120. 2014. View Article : Google Scholar : PubMed/NCBI
17	Cheung R, Kelly J and Macleod RJ: Regulation of villin by wnt5a/ror2 signaling in human intestinal cells. Front Physiol. 2:582011. View Article : Google Scholar : PubMed/NCBI
18	O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier M, et al: The orphan tyrosine kinase receptor, ROR2, mediates wnt5A signaling in metastatic melanoma. Oncogene. 29:34–44. 2010. View Article : Google Scholar : PubMed/NCBI
19	Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, et al: ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 227:223–233. 2012. View Article : Google Scholar : PubMed/NCBI
20	Wright TM and Rathmell WK: Identification of Ror2 as a hypoxia-inducible factor target in von hippel-lindau-associated renal cell carcinoma. J Biol Chem. 285:12916–12924. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, et al: Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene. 28:2513–2523. 2009. View Article : Google Scholar : PubMed/NCBI
22	Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M and Minami Y: Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 28:3197–3208. 2009. View Article : Google Scholar : PubMed/NCBI
23	McDonald SL and Silver A: The opposing roles of Wnt-5a in cancer. Br J Cancer. 101:209–214. 2009. View Article : Google Scholar : PubMed/NCBI
24	Nomachi A, Nishita M, Inaba D, Enomoto M, Hamasaki M and Minami Y: Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. J Biol Chem. 283:27973–27981. 2008. View Article : Google Scholar : PubMed/NCBI
25	Sun B, Ye X, Lin L, Shen M and Jiang T: Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer. Int J Clin Exp Pathol. 8:856–861. 2015.PubMed/NCBI
26	Lara E, Calvanese V, Huidobro C, Fernández AF, Moncada-Pazos A, Obaya AJ, Aguilera O, González-Sancho JM, Sánchez L, Astudillo A, et al: Epigenetic repression of ROR2 has a Wnt-mediated, pro-tumourigenic role in colon cancer. Mol Cancer. 9:1702010. View Article : Google Scholar : PubMed/NCBI